Evaluation of the anti-biofilm potential of biosynthesized silver nanoparticles against Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infection patients in Zahedan, 2023

Qasemi, Ali; Azizian-Shermeh, Omid; Rahimi, Fateh

doi:10.61186/CNJ.2.3.357

Evaluation of the anti-biofilm potential of biosynthesized silver nanoparticles against Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infection patients in Zahedan, 2023

Document Type : Original Article

Authors

Ali Qasemi ¹

Omid Azizian-Shermeh ²

Fateh Rahimi ³

¹ Department of Biology, Faculty of Basic Sciences, University of Sistan and Baluchestan, Zahedan, Iran

² Department of Chemistry, Faculty of Basic Sciences, University of Sistan and Baluchestan, Zahedan, Iran

³ Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

10.61186/CNJ.2.3.357

Abstract

Urinary tract infections (UTIs) are among the most prevalent infections worldwide and a significant contributor to morbidity and mortality, with bacterial biofilm formation playing a critical role in their persistence and resistance to treatment. This study evaluated the biofilm-forming ability of Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates obtained from UTI patients and investigated the anti-biofilm activity of biosynthesized silver nanoparticles (AgNPs) against biofilm-producing strains. Bacterial identification and confirmation were performed using selective culture media and polymerase chain reaction (PCR) assays. Biofilm production and the anti-biofilm efficacy of AgNPs were assessed through a quantitative microtiter plate assay, while antimicrobial susceptibility testing was conducted using standard antibiotic disc diffusion methods. The results revealed a high prevalence of biofilm-positive strains, with E. coli exhibiting a higher proportion of strong biofilm producers compared to K. pneumoniae. Antibiotic resistance analysis demonstrated significant resistance in both uropathogens, particularly to beta-lactam antibiotics. The synthesized AgNPs exhibited potent anti-biofilm activity, effectively inhibiting biofilm formation in both bacterial species. Interestingly, despite the higher biofilm-forming capacity of E. coli, AgNPs displayed greater inhibitory effects on E. coli biofilms compared to those of K. pneumoniae. These findings underscore the clinical relevance of biofilm formation in UTI pathogenesis and highlight biosynthesized AgNPs as a promising therapeutic agent for managing biofilm-associated infections. This study emphasizes the need for innovative approaches to combat biofilm-related antimicrobial resistance and improve UTI treatment outcomes.

Keywords

Urinary tract infection

Uropathogenic Escherichia coli

Klebsiella pneumoniae

Anti-biofilm activity

Silver nanoparticles

[1] A. L. Flores-Mireles, J. N. Walker, M. Caparon, S. J. Hultgren, Urinary tract infections: epidemiology, mechanisms
of infection and treatment options. Nat. Rev. Microbiol., 13(5) (2015) 269–284. https://doi.org/10.1038/nrmicro3432.
[2] T. M. Hooton, Uncomplicated urinary tract infection. N. Engl. J. Med., 366(11) (2012) 1028–1037.
https://doi.org/10.1056/NEJMcp1104429.
[3] A. L. Flores-Mireles, J. S. Pinkner, M. G. Caparon, S. J. Hultgren, E. coli biofilms and catheter-associated urinary
tract infections. Pathog. Dis., 70(2) (2014) 210–214. https://doi.org/10.1111/2049-632X.12145.
[4] J. B. Kaper, J. P. Nataro, H. L. Mobley, Pathogenic Escherichia coli. Nat. Rev. Microbiol., 2 (2014) 123–140.
https://doi.org/10.1038/nrmicro818.
[5] Z. Naziri, J. A. Kilegolan, M. S. Moezzi, A. Derakhshandeh, Biofilm formation by uropathogenic Escherichia
coli: a complicating factor for treatment and recurrence of urinary tract infections. J. Hosp. Infect., 117 (2021) 9–16.
https://doi.org/10.1016/j.jhin.2021.08.006.
[6] R. Abbas, M. Chakkour, H. Zein El Dine, E. F. Obaseki, S. T. Obeid, A. Jezzini, G. Ghssein, Z. Ezzeddine, General
Overview of Klebsiella pneumonia: Epidemiology and the Role of Siderophores in Its Pathogenicity. Biology (Basel),
13(2) (2024) 78. https://doi.org/10.3390/biology13020078.
[7] S. Clegg, C. N. Murphy, Epidemiology and Virulence of Klebsiella pneumoniae. Microbiol. Spectr., 4(1) (2016).
https://doi.org/10.1128/microbiolspec.UTI-0005-2012.
[8] A. Husna, M. M. Rahman, A. T. M. Badruzzaman, M. H. Sikder, M. R. Islam, M. T. Rahman, J. Alam, H. M.
Ashour, Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities. Biomedicines, 11(11) (2023)
2937. https://doi.org/10.3390/biomedicines11112937.
[9] B. Kot, Antibiotic Resistance Among Uropathogenic Escherichia coli. Pol. J. Microbiol., 68(4) (2019) 403–415.
https://doi.org/10.33073/pjm-2019-044.

[10] M. Desvaux, G. Dalmasso, R. Beyrouthy, N. Barnich, J. Delmas, R. Bonnet, Pathogenicity Factors of Genomic
Islands in Intestinal and Extraintestinal Escherichia coli. Front. Microbiol., 11 (2020) 2065.
https://doi.org/10.3389/fmicb.2020.02065.
[11] E. Sánchez-López, D. Gomes, G. Esteruelas, L. Bonilla, A. L. Lopez-Machado, R. Galindo, A. Cano, M. Espina,
M. Ettcheto, A. Camins, A. M. Silva, A. Durazzo, A. Santini, M. L. Garcia, E. B. Souto, Metal-Based Nanoparticles
as Antimicrobial Agents: An Overview. Nanomaterials (Basel), 10(2) (2020) 292.
https://doi.org/10.3390/nano10020292.
[12] N. Joudeh, D. Linke, Nanoparticle classification, physicochemical properties, characterization, and applications:
a comprehensive review for biologists. J. Nanobiotechnol., 20 (2022) 262. https://doi.org/10.1186/s12951-022-01516-
4.
[13] A. G. Kolhatkar, A. C. Jamison, D. Litvinov, R. C. Willson, T. R. Lee, Tuning the magnetic properties of
nanoparticles. Int. J. Mol. Sci., 14(8) (2013) 15977–16009. https://doi.org/10.3390/ijms140815977.
[14] J. H. Jorgensen, M. A. Pfaller, K. C. Carroll, et al., Manual of Clinical Microbiology. 12th ed., ASM Press,
Washington, DC (2019).
[15] M. Vareille, T. de Sablet, T. Hindré, C. Martin, A. P. Gobert, Nitric Oxide Inhibits Shiga-toxin Synthesis by
Enterohemorrhagic Escherichia coli. Proc. Natl. Acad. Sci. USA, 104(24) (2007) 10199–10204.
https://doi.org/10.1073/pnas.0700399104.
[16] Y. Kai-Larsen, P. Lüthje, M. Chromek, V. Peters, X. Wang, A. Holm, et al., Uropathogenic Escherichia coli
modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog., 6(7)
(2010) e1001010. https://doi.org/10.1371/journal.ppat.1001010.
[17] G. A. O’Toole, Microtiter dish biofilm formation assay. J. Vis. Exp., 30(47) (2011) 2437.
https://doi.org/10.3791/2437.
[18] CLSI, Performance Standards for Antimicrobial Susceptibility Testing. 31st ed., CLSI Supplement M100,
Clinical and Laboratory Standards Institute, Wayne, PA (2021).
[19] Q. W. Zhang, L. G. Lin, W. C. Ye, Techniques for extraction and isolation of natural products: a comprehensive
review. Chin. Med., 13 (2018) 20. https://doi.org/10.1186/s13020-018-0177-x.
[20] A. Bukhari, I. Ijaz, E. Gilani, A. Nazir, H. Zain, R. Saeed, et al., Green Synthesis of Metal and Metal Oxide
Nanoparticles Using Different Plants’ Parts for Antimicrobial Activity and Anticancer Activity: A Review Article.
Coatings, 11(11) (2021) 1374. https://doi.org/10.3390/coatings11111374.
[21] S. Mourdikoudis, R. M. Pallares, N. T. K. Thanh, Characterization techniques for nanoparticles: comparison and
complementarity upon studying nanoparticle properties. Nanoscale, 10(27) (2018) 12871–12934.
https://doi.org/10.1039/C8NR02278J.
[22] J. H. Jorgensen, M. J. Ferraro, Antimicrobial susceptibility testing: a review of general principles and
contemporary practices. Clin. Infect. Dis., 49(11) (2009) 1749–1755. https://doi.org/10.1086/647952.
[23] M. Balouiri, M. Sadiki, S. K. Ibnsouda, Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm.
Anal., 6(2) (2016) 71–79. https://doi.org/10.1016/j.jpha.2015.11.005.
[24] E. Lo, L. E. Nicolle, S. E. Coffin, C. Gould, L. L. Maragakis, J. Meddings, et al., Strategies to prevent catheterassociated urinary tract infections in acute care hospitals: 2014 update. Infect. Control Hosp. Epidemiol., 35(5) (2014)
464–479. https://doi.org/10.1086/675718.
[25] M. Mohammadzadeh, M. Tavakoli, S. Yaslianifard, E. Asadi, R. Golmohammadi, R. Mirnejad, Genetic diversity
and antibiotic susceptibility of uropathogenic Escherichia coli isolates from kidney transplant recipients. Infect. Drug
Resist., 12 (2019) 1795–1803. https://doi.org/10.2147/IDR.S207047.
[26] D. Sharma, L. Misba, A. U. Khan, Antibiotics versus biofilm: an emerging battleground in microbial
communities. Antimicrob. Resist. Infect. Control, 8(1) (2019) 76. https://doi.org/10.1186/s13756-019-0533-3.
[27] C. Becker, S. Graf, A. Mews, W. J. Parak, I. Chakraborty, ChemNanoMat, 10 (2024) e202300453.
https://doi.org/10.1002/cnma.202300453.
[28] W. R. Li, X. B. Xie, Q. S. Shi, S. S. Duan, Y. S. Ouyang, Y. B. Chen, Antibacterial effect of silver nanoparticles
on Staphylococcus aureus. Biometals, 24(1) (2011) 135–141. https://doi.org/10.1007/s10534-010-9381-6.

[29] V. Patel, D. Berthold, P. Puranik, M. Gantar, Screening of cyanobacteria and microalgae for their ability to
synthesize silver nanoparticles with antibacterial activity. Biotechnol. Rep. (Amst.), 5 (2014) 112–119.
https://doi.org/10.1016/j.btre.2014.12.001.
[30] A. Rezaei, A. Farzinpour, A. Vaziry, A. Jalili, Effects of Silver Nanoparticles on Hematological Parameters and
Hepatorenal Functions in Laying Japanese Quails. Biol. Trace Elem. Res., 185(2) (2018) 475–485.
https://doi.org/10.1007/s12011-018-1265-7.
[31] J. Lellouche, A. Friedman, A. Gedanken, E. Banin, Antibacterial and antibiofilm properties of yttrium fluoride
nanoparticles. Int. J. Nanomedicine, 7 (2012) 5611–5624. https://doi.org/10.2147/IJN.S35658.
[32] N. Musee, M. Thwala, N. Nota, The antibacterial effects of engineered nanomaterials: implications for wastewater
treatment plants. J. Environ. Monit., 13(5) (2011) 1164–1183. https://doi.org/10.1039/C0EM00717A.
[33] M. Krychowiak, A. Kawiak, M. Narajczyk, A. Borowik, A. Królicka, Silver Nanoparticles Combined With
Naphthoquinones as an Effective Synergistic Strategy Against Staphylococcus aureus. Front. Pharmacol., 9 (2018)
816. https://doi.org/10.3389/fphar.2018.00816.
[34] A. Qasemi, F. Rahimi, M. Katouli, Clonal groups of extended-spectrum β-lactamase and biofilm producing
uropathogenic Escherichia coli in Iran. Pathog. Glob. Health, 116(8) (2022) 485–497.
https://doi.org/10.1080/20477724.2022.2140118.
[35] S. Iravani, H. Korbekandi, S. V. Mirmohammadi, B. Zolfaghari, Synthesis of silver nanoparticles: chemical,
physical and biological methods. Res. Pharm. Sci., 9(6) (2014) 385–406. https://doi.org/10.4103/1735-5362.144510.